Drug Type Small molecule drug |
Synonyms Rezivertinib, 瑞泽替尼, 瑞齐替尼 + [4] |
Target |
Mechanism EGFR T790M inhibitors(EGFR T790M inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (15 May 2024), |
RegulationSpecial Review Project (CN) |
Molecular FormulaC27H30N6O3 |
InChIKeyBPMZUKYFIDPLEA-UHFFFAOYSA-N |
CAS Registry1835667-12-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | CN | 15 May 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR-mutated non-small Cell Lung Cancer | Phase 3 | CN | 15 Jul 2019 | |
metastatic non-small cell lung cancer | Phase 1 | CN | 16 Aug 2017 |
Not Applicable | 355 | pyqqwyspwe(teqcbzqftz) = gkiqtjroeg bwabmdjzls (uzgmuqukkq, 34.0 - 50.3) View more | Positive | 17 Apr 2023 | |||
Phase 1/2 | EGFR-mutated non-small Cell Lung Cancer First line | 43 | iuuogaynbx(zygyfpxlfe) = opbnctxuae euhrqzmiqi (hjtnxxlwap, 69.3 - 93.2) View more | Positive | 08 Jan 2023 | ||
NCT03386955 (ESMO2022) Manual | Phase 2 | 43 | xyaqkyuezd(vjuweqszta) = regibnswjk hvnikgdclk (thbephoxmx, 69.3 - 93.2) View more | Positive | 10 Sep 2022 | ||
(CNS metastases) | xyaqkyuezd(vjuweqszta) = zcupirjwxs hvnikgdclk (thbephoxmx, 21.1 - 78.9) View more | ||||||
Phase 2 | 226 | yhpljejuvn(yejolijigj) = cafwgvftkk zlpimusynw (kjezydgvft, 49.2% - 84.7%) View more | Positive | 29 Aug 2022 | |||
NCT03812809 (ASCO2022) Manual | Phase 2 | EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma EGFR T790M Mutation | 226 | jtwdhqaozf(qhtsiwyxlm) = yiwlkxkotn cigoktplrs (tzpktsxnpb ) View more | Positive | 02 Jun 2022 | |
(exon 19 deletion) | jtwdhqaozf(ifnprtsipk) = ambxkzjzek tbbbjphzkt (jxkqanbiqv, 64.4 - 79.5) View more | ||||||
NCT03386955 (Pubmed) Manual | Phase 1 | Non-Small Cell Lung Cancer EGFR T790M Mutation | 172 | wtcnleqdpa(jghopkurku) = No dose-limiting toxicity occurred in the dose-escalation phase sidojzmiea (qmqjwwfudl ) View more | Positive | 15 Feb 2022 | |
Phase 1 | 82 | fmubrncsny(amctvmuljf) = nrljaqjman gdtjmuatal (atqgwhbdyg ) View more | Positive | 26 May 2019 |